ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GDR Genedrive Plc

5.375
-0.75 (-12.24%)
Last Updated: 12:44:58
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75 -12.24% 5.375 5.00 5.75 6.25 5.125 6.25 2,487,686 12:44:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 55k -5.15M -0.0447 -1.26 6.47M
Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 6.13p. Over the last year, Genedrive shares have traded in a share price range of 2.75p to 25.75p.

Genedrive currently has 115,139,946 shares in issue. The market capitalisation of Genedrive is £6.47 million. Genedrive has a price to earnings ratio (PE ratio) of -1.26.

Genedrive Share Discussion Threads

Showing 1 to 7 of 25300 messages
Chat Pages: Latest  4  3  2  1
DateSubjectAuthorDiscuss
15/9/2016
14:28
monitoring this closely
the ghost who walks
09/9/2016
22:25
I also continue to monitor closely. I also stand by my previous post!
azzi
02/9/2016
18:52
Looking forward to the next updateMonitoring closely
the ghost who walks
25/8/2016
18:34
Monitoring the updates
the ghost who walks
22/8/2016
07:34
Closely following the updates
the ghost who walks
22/8/2016
07:34
Monitoring this one closely.
the ghost who walks
16/8/2016
19:23
No significant share price response at all to recent updates. The Tb assay is now scheduled for launch in 2017, BUT, the company must be aware of the feedback from its Indian distributors by now, remember this is their flag ship right now. On the face of it, positive news for their HCV/IL28 assay, however placing 20 gene drives and only 400 assays (that's 20 assays per gene drive!) is small scale proof of principle stuff, I thought they were way beyond that!
It feels the company are drifting aimlessly, just hoping that a good result will emerge and provide a way forward. For me this is the problem, there is no obvious on going development/problem solving of their technology. Something has changed. It feels like they need some decent R&D input, I really don't think they have this right now, so it's time to go looking for the right people who can help them out of their malaise.
For the record, I am still a potential investor, just need some real proof that they have worthwhile assay technology.

azzi
Chat Pages: Latest  4  3  2  1

Your Recent History

Delayed Upgrade Clock